Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Hyperhomocysteinemia (HHcy) and chronic kidney disease (CKD) are established risk factors for cardiovascular events and all-cause mortality. Their coexistence may further amplify these risks, particularly in patients with mild-to-moderate CKD; however, whether the coexistence confers a higher risk than either condition alone remains unclear.
In this retrospective analysis of a prospective observational cohort, we analyzed health checkup data from 3,377 residents aged ≥40 years living in Takahata, Japan. Baseline data were collected between 2004 and 2006. Eligibility for inclusion required an estimated glomerular filtration rate (eGFR) of ≥30 mL/min/1.73 m² at baseline. The primary and secondary endpoints were all-cause mortality and cardiovascular events, respectively. Participants were stratified according to the presence or absence of HHcy and mild-to-moderate CKD. Cumulative incidence of the endpoints was assessed using the Kaplan–Meier method, and the risk of events was evaluated by Cox proportional hazards regression analysis.
The median follow-up period was 18.6 years (interquartile range, 17.2–19.3). Kaplan–Meier analyses revealed that individuals with both HHcy and CKD had the highest incidence of all-cause mortality and cardiovascular events (log-rank p < 0.001 for both). After adjustment for cardiovascular risk factors, this group remained at the highest risk, with hazard ratios (HRs) of 2.49 (95% confidence interval (CI), 2.00–3.10) for all-cause mortality and 2.11 (95% CI, 1.32–3.38) for cardiovascular events, respectively. Upon stratifying the group with both HHcy and CKD into CKD G1/2 and CKD G3 according to the KDIGO classification, both subgroups showed comparably high risks, with HRs for all-cause mortality of 2.49 (95% CI, 1.96–3.18 and 1.89–3.27, respectively) and HRs for cardiovascular events of 2.11 (95% CI, 1.26–3.56 and 1.15–3.86, respectively).
In the Japanese general population aged ≥40 years, the coexistence of HHcy and mild-to-moderate CKD was associated with a significantly higher risk of all-cause mortality and cardiovascular events than either condition alone.
